Plain-English translation of NCT06276465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
PEACE 8 is testing whether adding a type of focused radiation therapy called stereotactic body radiation therapy (SBRT) to darolutamide — a hormone-blocking medication — helps treat advanced prostate cancer that has spread to a few places in the body. All participants will receive hormone therapy (called castration therapy) plus darolutamide, and half will also receive the focused radiation treatment to their cancer sites. The study will follow participants for up to 5 years.
Standard hormone therapy alone can slow this type of advanced prostate cancer, but cancer often continues to grow. Researchers want to know if adding focused radiation directly to the cancer spots — while continuing the medication — might help people live longer and delay the cancer from getting worse.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one receiving hormone therapy plus the medication darolutamide, and another receiving the same plus focused radiation therapy to your cancer spots. You will visit the hospital regularly for medical check-ups before each treatment dose, blood tests, and imaging scans to monitor your health and how well the treatment is working. Your participation will last up to 5 years, with treatment continuing until your cancer progresses or you experience unacceptable side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France